Feasibility, troubleshooting and development strategy: common questions answered.

The highest-value points are before investor discussions or grant applications; before committing significant development spend; three to six months before CDMO transfer, scale-up or partner engagement; and when assay performance issues are slowing progress. At these points, independent review can clarify what the evidence supports before decisions become costly to reverse.

External expertise is most useful when data is unclear, inconsistent or difficult to interpret in the context of a development, funding or investment decision. Independent input helps separate what is genuinely supported from what is assumed, optimistic or not yet assessed.

A fixed-scope review of your data, methods and history, typically over 2–4 weeks, with the scope agreed in writing beforehand. You receive a ranked assessment of likely causes, a prioritised investigation plan and a decision on what to test next, followed by a debrief with your team.

Yes. ORIVISE provides structured technical review to identify likely drivers of variability, instability or poor performance. The aim is to distinguish between assay architecture, reagent behaviour, bioconjugation, matrix effects and process variables, then define a focused investigation route rather than testing everything sequentially.

High variability is often caused by underlying system instability rather than a single parameter. Common contributors include reagent instability, inconsistent bioconjugation, lot-to-lot differences, matrix effects, assay-condition sensitivity and operator-dependent steps. Identifying the dominant factor requires structured root-cause analysis.

High background is often driven by non-specific interactions, inadequate blocking, non-specific antibody binding, matrix effects, suboptimal antibody concentration, wash conditions or surface chemistry. In particle-based systems, aggregation of labelled reagents can also contribute to elevated background.

Common issues include inconsistent coupling efficiency, loss of biological activity during conjugation, aggregation of labelled particles or proteins, instability during storage or assay use, and lot-to-lot variability. These issues can directly affect sensitivity, specificity and reproducibility.

Reproducibility improves by identifying and controlling the variables that most influence performance, including reagent stability, lot consistency, buffer conditions, pH, temperature, incubation time, conjugation robustness and operator technique. Persistent reproducibility problems may indicate that the assay architecture or reagent strategy needs deeper review.

Before scale-up, the assay should show consistent performance across defined conditions, controlled reagent variability, robust critical parameters and evidence that performance can translate beyond a single optimised laboratory setting. Unresolved small-scale variability often amplifies during transfer or manufacturing.

Transfer failures often occur because critical assay parameters, reagent scalability, formulation stability, operator independence or environmental sensitivities were not fully characterised before transfer. What looks acceptable in one laboratory setting may shift when reagent lots, equipment, operators or conditions change.

An assay is development-ready when it has stable and reproducible performance across defined conditions, a mature reagent strategy, clearly defined critical parameters, evidence across multiple runs or operators, and a technical plan suitable for the next decision: transfer, investment, partnering or regulated development.

ORIVISE provides independent technical evaluation and decision support, not laboratory execution. CROs generate data; ORIVISE helps define the right technical questions, assess existing evidence, identify risk and clarify what additional work is needed before resources are committed.

No. ORIVISE provides advisory input rather than laboratory execution. Where further experiments are needed, ORIVISE can help define the experimental direction and identify the type of laboratory partner required.

Outputs depend on the agreed scope, but ORIVISE engagements are designed to support a specific technical or investment decision. Typical outputs may include an independent technical review, evidence-gap summary, prioritised technical risks and recommended next steps. More detailed reports, due-diligence memos or troubleshooting plans are agreed as part of the engagement scope.

ORIVISE primarily supports immunoassays including ELISA, lateral flow, particle-based and bead-based systems, with depth in assay architecture, reagent strategy, bioconjugation and analytical performance. The approach can also support point-of-care, biosensor-based and other diagnostic platforms where feasibility and development risk need independent review.

ORIVISE reviews technical data-room materials, pitch claims and supporting evidence to identify red flags, unsupported claims, missing evidence, reproducibility risks and technical questions investors should raise before committing capital.

Yes. ORIVISE can support grant-led diagnostic translation by reviewing feasibility rationale, evidence gaps, development risks and technical work packages, helping academic teams, TTOs and spin-outs present a more credible development plan.

Yes. We can discuss a scoped engagement for selected diagnostics ventures, combining initial technical assessment with mentoring at agreed review points. The format, outputs and reporting boundaries depend on the programme.

ORIVISE can assess the technical case, strengthen development evidence and raise questions about intended use and workflow early. Clinical evaluation, health economics, procurement and implementation require relevant partners and evidence. Their involvement would be planned according to the project.

Assay feasibility assesses whether an IVD assay can realistically achieve the required sensitivity, specificity, reproducibility and robustness under practical development conditions. It matters because promising science can still fail if feasibility assumptions are not tested against the decision being made, such as whether to invest, transfer, partner or enter structured development.

Before structured IVD development, teams usually need preliminary analytical performance evidence in a relevant sample matrix, initial reproducibility data, a defined assay architecture, a reagent strategy, clarity on key variables affecting performance, and an intended use or target product profile. Without this, development work can generate data that does not support the next decision.

Technical debt arises when unresolved assumptions, characterisation gaps or weak feasibility evidence are carried forward into development. It often appears later as unexpected variability, failed transfer, repeated characterisation work or difficulty demonstrating reproducibility. Addressing technical debt early is usually less costly than correcting it during scale-up, CDMO transfer or regulated development.